2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission Tomography/Computed Tomography in the Management of Melanoma

Abstract

This study confirms the good results of FDG-PET/CT for residual/recurrent melanoma detection, as well as for distant metastases localization. PET/CT should be an integral part in evaluation of patients with high-risk melanoma, prior to selection of the most appropriate therapy.

Lymphatic drainage patterns of head and neck cutaneous melanoma: does primary melanoma site correlate with anatomic distribution of pathologically involved lymph nodes?

“…Although PET's inability to identify microscopic disease suggest that is of limited use in evaluating patients with stage I-II disease, PET can be helpful in managing patients with stage III melanoma in whom further surgery is contemplated 38 . Furthermore, Iagaru et al 18 showed that PET has a sensitivity of 89% and a specificity of 88% for melanoma detection during restaging, and therefore should be an integral part in evaluation of patients with high-risk melanoma, prior to selection of the optimal treatment modality.…”

Determination of Melanoma Lateral and Depth Margins: Potential for Treatment Planning and Five-Year Survival Rate

“…Reinhardt et al studied 251 patients with PET/CT and showed a sensitivity of 98.7% compared to 88.8% for PET alone and 69.7% for CT alone (Reinhardt et al, 2006). Moreover, Iagaru et al recently reported a study involving 163 patients and showed a sensitivity of 89%, and recommended the use of PET/CT in the evaluation of high-risk CMM metastasis (Iagaru et al, 2006). Fig.…”

Clinical applications of positron emission tomography-computed tomography in oncology

“…Iagaru et al showed that PET/CT has 89% sensitivity and 88% specificity for melanoma lesion detection during restaging, especially in high risk patients. [72] False Negative: PET/PET-CT has limited value for early diagnosis (stage I-II) of the disease. PET is relatively insensitive as compared to SLN biopsy for detection of early nodal disease.…”